<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078376</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-491_109</org_study_id>
    <secondary_id>2009-013165-25</secondary_id>
    <secondary_id>U1111-1113-4416</secondary_id>
    <nct_id>NCT01078376</nct_id>
  </id_info>
  <brief_title>A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults</brief_title>
  <official_title>A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents With Hypertension and Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose
      of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Within the past 10 years, the incidence of high blood pressure (hypertension) in children and
      adolescents has increased all over the world. This increase is connected in part to a growing
      number of people who are overweight and do not eat right or exercise enough. In younger
      children though, high blood pressure is a common consequence of underlying diseases, such as
      renal diseases.

      This study looked at a blood pressure medicine called TAK-491 (azilsartan medoxomil) to see
      how it works in children who have hypertension. Azilsartan medoxomil is a prodrug that
      converts into TAK-536 (azilsartan), a blood pressure lowering medicine that had not been
      tested in children.

      To be eligible to take part in this study, children with a diagnosis of hypertension (primary
      or secondary) must have been between the ages of 1 year and 16 years old (up to their 17th
      birthday). Each child was given one dose of azilsartan medoxomil, followed by a number of
      blood tests and assessments within 24 hours after taking azilsartan medoxomil to see how the
      medication is working. Adults who do not have hypertension also took part in this study to
      provide comparison.

      This study took place in 9 sites in the UK and USA. A total of 20 children with hypertension
      and 9 adults without hypertension participated in this study.

      This study lasted about 43 days. This included a 28 day screening period, a 2 day treatment
      phase and a follow up period. Each participant taking part in this study may have been
      requested to remain in a hospital for one overnight stay during the course of the study. Each
      participant was contacted by telephone 6 days and 15 days after taking azilsartan medoxomil.

      Takeda has decided to close Cohort 3 (participants between 1 and 6 years of age with
      hypertension) enrollment early and end this study with the agreement of both the US Food and
      Drug Administration (FDA) and the Pediatric Committee (PDCO) at the European Medicines
      Agency. Requests to the FDA and PDCO were submitted to close the study without completion of
      enrollment in Cohort 3 due to difficulty enrolling this particular patient population. Takeda
      proposed an alternative option to collect PK data in this age subset by utilizing PK modeling
      to determine the appropriate doses in children 1-5 years of age in lieu of completing Cohort
      3. The FDA and PDCO agreed with this approach.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Decision (see below)
  </why_stopped>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II.</measure>
    <time_frame>Day 1</time_frame>
    <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II</measure>
    <time_frame>Day 1</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for TAK-536</measure>
    <time_frame>Day 1</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II</measure>
    <time_frame>Day 1</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Cmax (Tmax) for TAK-536</measure>
    <time_frame>Day 1</time_frame>
    <description>Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II</measure>
    <time_frame>Day 1</time_frame>
    <description>Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) for TAK-536</measure>
    <time_frame>Day 1</time_frame>
    <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II</measure>
    <time_frame>Day 1</time_frame>
    <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F) for TAK-536</measure>
    <time_frame>Day 1</time_frame>
    <description>CL/F is apparent clearance of the drug from the plasma, expressed in L/hr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)</measure>
    <time_frame>Day 1</time_frame>
    <description>Fe=[Ae(0-24)/dose]×100 (molecular weight adjusted for metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)</measure>
    <time_frame>Day 1</time_frame>
    <description>Fe=[Ae(0-24)/dose]×100 (molecular weight adjusted for metabolites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)</measure>
    <time_frame>Day 1</time_frame>
    <description>Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)</measure>
    <time_frame>Day 1</time_frame>
    <description>Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Healthy Adults (18 years to 45 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Adolescents (≥12 to &lt;17 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Children (≥6 to &lt;12 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Children (≥1 to &lt;6 years old)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil (TAK-491)</intervention_name>
    <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
    <arm_group_label>Cohort 1: Healthy Adults (18 years to 45 years old)</arm_group_label>
    <other_name>TAK-491</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil (TAK-491)</intervention_name>
    <description>Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only</description>
    <arm_group_label>Cohort 1: Adolescents (≥12 to &lt;17 years old)</arm_group_label>
    <other_name>TAK-491</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil (TAK-491)</intervention_name>
    <description>Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only</description>
    <arm_group_label>Cohort 2: Children (≥6 to &lt;12 years old)</arm_group_label>
    <other_name>TAK-491</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil (TAK-491)</intervention_name>
    <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
    <arm_group_label>Cohort 3: Children (≥1 to &lt;6 years old)</arm_group_label>
    <other_name>TAK-491</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For Pediatric Participants:

        Must have a diagnosis of hypertension (SBP and/or DBP ≥95th percentile for
        age/gender/height).

          -  For Cohorts 1 and 2 only, is within the weight range of 20 kg (44 pounds) to 100 kg
             (220 pounds), inclusive, at Screening.

          -  For Cohort 3 only, weighs at least 8.0 kg (17.6 pounds) at Screening.

          -  Participants greater than or equal to 6 years of age must have the ability to swallow
             a tablet of the size 6.0 millimeter diameter and 3.5 millimeter thickness.

          -  Has no known history of hepatitis B, hepatitis C, and human immunodeficiency virus.

          -  For Cohort 3 only, may be renal transplant patient if all other inclusion and none of
             the exclusion criteria are met, along with additional criteria.

          -  Must have been at a constant weight, or expected weight gain for that particular age,
             for 30 days with no change to the dose of their diuretic drugs.

        For Healthy Adult Participants:

          -  Weighs at least 50 kilograms (110 pounds) and has a screening body mass index between
             18 and 32 kilograms/m2, inclusive.

          -  Is in good health as determined by the physician

          -  Has a negative test result for hepatitis B surface antigen and antibody to hepatitis C
             virus, and has no known history of human immunodeficiency virus.

          -  Must have a negative urine test result for selected substances of abuse .

          -  Has a diastolic blood pressure between 60 and 90 mm Hg, inclusive, and a systolic
             blood pressure between 100 and 140 mm Hg, inclusive.

        For All Participants:

          -  Females of child bearing potential who are sexually active, as well as sexually active
             male participants, agree to routinely use adequate contraception from Screening until
             30 days after receiving the last dose of study medication.

          -  Has clinical laboratory results within the reference range for the testing laboratory
             unless the results are deemed not clinically significant by the investigator.

        Exclusion Criteria:

        For Pediatric Participants:

          -  Is currently treated with more than 2 antihypertensive agents.

          -  Has sitting trough clinic systolic blood pressure greater than 15 mm Hg or diastolic
             blood pressure greater than 10 mm Hg above the 99th percentile for age, gender, and
             height at Check-in .

          -  Has renovascular disease affecting both kidneys or a solitary kidney, dialysis
             treatment, severe nephrotic syndrome and not in remission.

          -  For Cohort 1 and 2 only, a previous renal transplant.

          -  Has a creatinine clearance less than 30 mL/min/1.73 m2.

        For all participants:

          -  Has previously received azilsartan or azilsartan medoxomil.

          -  Has a known hypersensitivity or allergy to any angiotensin type II receptor blockers
             or to any of the excipients in the azilsartan medoxomil formulation to be taken.

          -  Has a history or clinical manifestations of severe cardiovascular disease, psychiatric
             disease, and any conditions that would interfere with gastrointestinal absorption.

          -  Has hemodynamically significant left ventricular outflow obstruction due to aortic
             valvular disease, cardiomyopathy, or uncorrected coarctation of the aorta.

          -  Has been diagnosed with malignant or accelerated hypertension.

          -  Has severe hepatic impairment.

          -  Has a serum albumin less than 2.5 g/dL.

          -  Has a glycosylated hemoglobin value greater than 8.5%.

          -  Has alanine aminotransferase, aspartate aminotransferase greater than 2 times the
             upper limit of normal, or total bilirubin greater than 1.5 times the upper limit of
             normal, active liver disease, or jaundice.

          -  Has hyperkalemia as defined by the laboratory normal reference range or any pertinent
             electrolyte disorders.

          -  Is participating in another investigational study or has taken an investigational drug
             within 30 days prior to Check-in .

          -  Has a history of drug abuse or a history of alcohol abuse within 1 year prior to study
             Check-in.

          -  Has a history of abdominal surgery or thoracic or nonperipheral vascular surgery
             within 6 months prior to study Check-in.

          -  Has a history of cancer, other than basal cell carcinoma or stage I squamous cell
             carcinoma of the skin that has not been in remission for at least 5 years prior to
             study Check-in.

          -  Has taken any cytotoxic drugs within 12 months prior to study Check-in .

          -  Has a history or presence of a clinically significant abnormal 12-lead
             electrocardiogram as determined by the investigator or sponsor/designee.

          -  Has poor peripheral venous access.

          -  Has any other condition or prior therapy that, in the opinion of the investigator,
             would make the participant unsuitable for the study.

          -  Has taken or requires the use of any medications, supplements, or food products within
             the stated time periods, including:

               -  Pediatric participants taking angiotensin-converting enzyme inhibitors and other
                  angiotensin II receptor blockers will be required to withhold these medications
                  from the morning of Day -1 until the 24 hour pharmacokinetic sample is completed
                  on Day 2.

               -  Only pediatric participants will be allowed to take medications for primary renal
                  or urologic conditions or hypertension as long as they have been on a stable dose
                  of their medication for at least 30 days prior to Check-in (Day -1) and those
                  medications are not potent cytochrome P-450 inhibitors or inducers.

               -  Nutraceuticals including herbal or dietary preparations such as ginseng, kava
                  kava, and ginkgo biloba.

               -  Over-the-counter medications.

               -  Vitamin supplements except for pediatric participants only.

               -  Alcohol-containing products.

               -  Products that contain caffeine or xanthine-related compounds.

               -  Foods or beverages containing grapefruit juice or Seville-type oranges.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <results_first_submitted>June 26, 2014</results_first_submitted>
  <results_first_submitted_qc>June 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2014</results_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <keyword>Blood Pressure, High</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 6 sites in the United States and 3 sites in the United Kingdom from 10 May 2010 to 10 July 2013.</recruitment_details>
      <pre_assignment_details>Children between the ages of 1 to 16 years (including up to their 17th birthday) with hypertension and gender-matched healthy adults aged 18 to 45 years, inclusive, were enrolled in 1 of 3 cohorts.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Healthy Adults</title>
          <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40-60 mg</title>
          <description>Azilsartan medoxomil 40-60 mg, tablets, orally, one day only. Dose regimen was based on body weight. Participants 40 to &lt; 80 kg received a 40 mg dose and participants 80 to 100 kg received a 60 mg dose.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20-60 mg</title>
          <description>Azilsartan medoxomil 20-60 mg, tablets, orally, one day only. Dose regimen was based on body weight. Participants 20 to &lt; 40 kg received a 20 mg dose, participants 40 to &lt; 80 kg received a 40 mg dose and participants 80 to 100 kg received a 60 mg dose.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
          <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Healthy Adults</title>
          <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40-60 mg</title>
          <description>Azilsartan medoxomil 40-60 mg, tablets, orally, one day only. Dose regimen was based on body weight. Participants 40 to &lt; 80 kg received a 40 mg dose and participants 80 to 100 kg received a 60 mg dose.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20-60 mg</title>
          <description>Azilsartan medoxomil 20-60 mg, tablets, orally, one day only. Dose regimen was based on body weight. Participants 20 to &lt; 40 kg received a 20 mg dose, participants 40 to &lt; 80 kg received a 40 mg dose and participants 80 to 100 kg received a 60 mg dose.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
          <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="7.78"/>
                    <measurement group_id="B2" value="14.2" spread="1.64"/>
                    <measurement group_id="B3" value="9.1" spread="2.10"/>
                    <measurement group_id="B4" value="4.7" spread="0.58"/>
                    <measurement group_id="B5" value="16.2" spread="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.6" spread="9.70"/>
                    <measurement group_id="B2" value="163.1" spread="11.72"/>
                    <measurement group_id="B3" value="138.6" spread="12.74"/>
                    <measurement group_id="B4" value="107.7" spread="11.06"/>
                    <measurement group_id="B5" value="153.6" spread="23.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.64" spread="11.207"/>
                    <measurement group_id="B2" value="71.71" spread="15.512"/>
                    <measurement group_id="B3" value="48.50" spread="22.523"/>
                    <measurement group_id="B4" value="18.30" spread="4.026"/>
                    <measurement group_id="B5" value="60.69" spread="23.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.06" spread="3.345"/>
                    <measurement group_id="B2" value="27.22" spread="6.611"/>
                    <measurement group_id="B3" value="24.29" spread="8.327"/>
                    <measurement group_id="B4" value="15.67" spread="0.551"/>
                    <measurement group_id="B5" value="24.54" spread="6.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536</title>
        <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536</title>
          <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40613" spread="9609.6"/>
                    <measurement group_id="O2" value="23889" spread="5383.8"/>
                    <measurement group_id="O3" value="17423" spread="3559.7"/>
                    <measurement group_id="O4" value="16056">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="22556" spread="5792.6"/>
                    <measurement group_id="O6" value="18691" spread="5489.9"/>
                    <measurement group_id="O7" value="16963" spread="4948.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II.</title>
        <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II.</title>
          <description>AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]).</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11563" spread="3106.5"/>
                    <measurement group_id="O2" value="7409" spread="78.6"/>
                    <measurement group_id="O3" value="7428" spread="2120.7"/>
                    <measurement group_id="O4" value="7392">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="7929" spread="3502.6"/>
                    <measurement group_id="O6" value="9130" spread="1338.3"/>
                    <measurement group_id="O7" value="7285" spread="3626.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536</title>
        <description>Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536</title>
          <description>Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44820" spread="11680.7"/>
                    <measurement group_id="O2" value="26411" spread="6703.1"/>
                    <measurement group_id="O3" value="18686" spread="3720.4"/>
                    <measurement group_id="O4" value="16563">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="23792" spread="6157.0"/>
                    <measurement group_id="O6" value="19543" spread="6181.1"/>
                    <measurement group_id="O7" value="17771" spread="5263.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II</title>
        <description>Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II</title>
          <description>Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>ng.hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19188" spread="6766.0"/>
                    <measurement group_id="O2" value="10596" spread="1168.8"/>
                    <measurement group_id="O3" value="12532" spread="3905.3"/>
                    <measurement group_id="O4" value="8961">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="11387" spread="5440.7"/>
                    <measurement group_id="O6" value="14230" spread="3419.6"/>
                    <measurement group_id="O7" value="9477" spread="4659.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) for TAK-536</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) for TAK-536</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5699" spread="1346.1"/>
                    <measurement group_id="O2" value="3245" spread="106.1"/>
                    <measurement group_id="O3" value="2512" spread="701.6"/>
                    <measurement group_id="O4" value="2810">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="3858" spread="1363.0"/>
                    <measurement group_id="O6" value="2960" spread="364.3"/>
                    <measurement group_id="O7" value="3320" spread="656.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="736" spread="241.6"/>
                    <measurement group_id="O2" value="480" spread="74.2"/>
                    <measurement group_id="O3" value="535" spread="200.2"/>
                    <measurement group_id="O4" value="514">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="561" spread="211.7"/>
                    <measurement group_id="O6" value="561" spread="40.3"/>
                    <measurement group_id="O7" value="488" spread="212.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Cmax (Tmax) for TAK-536</title>
        <description>Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Cmax (Tmax) for TAK-536</title>
          <description>Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.8819" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.01" spread="0.0118" lower_limit="2.00" upper_limit="2.02"/>
                    <measurement group_id="O3" value="2.00" spread="0.4082" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="2.00">Standard deviation or range cannot be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="2.00" spread="2.2043" lower_limit="1.05" upper_limit="6.00"/>
                    <measurement group_id="O6" value="2.00" spread="0.0096" lower_limit="1.98" upper_limit="2.00"/>
                    <measurement group_id="O7" value="1.00" spread="0.0000" lower_limit="1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II</title>
        <description>Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II</title>
          <description>Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="1.4227" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="5.00" spread="1.4142" lower_limit="4.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="6.00" spread="0.8256" lower_limit="4.00" upper_limit="6.10"/>
                    <measurement group_id="O4" value="6.00">Standard deviation or range cannot be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="4.03" spread="1.9890" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O6" value="4.00" spread="2.3094" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O7" value="6.0" spread="0.0000" lower_limit="6.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (T1/2) for TAK-536</title>
        <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) for TAK-536</title>
          <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.35" spread="1.083"/>
                    <measurement group_id="O2" value="7.74" spread="0.621"/>
                    <measurement group_id="O3" value="5.76" spread="1.158"/>
                    <measurement group_id="O4" value="5.07">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="5.75" spread="0.760"/>
                    <measurement group_id="O6" value="5.37" spread="0.922"/>
                    <measurement group_id="O7" value="4.59" spread="1.627"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II</title>
        <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II</title>
          <description>Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.60" spread="6.870"/>
                    <measurement group_id="O2" value="12.78" spread="2.915"/>
                    <measurement group_id="O3" value="14.00" spread="2.414"/>
                    <measurement group_id="O4" value="8.50">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="11.56" spread="3.314"/>
                    <measurement group_id="O6" value="13.97" spread="2.983"/>
                    <measurement group_id="O7" value="10.35" spread="2.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Oral Clearance (CL/F) for TAK-536</title>
        <description>CL/F is apparent clearance of the drug from the plasma, expressed in L/hr.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O7">
            <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
            <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Oral Clearance (CL/F) for TAK-536</title>
          <description>CL/F is apparent clearance of the drug from the plasma, expressed in L/hr.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="0.414"/>
                    <measurement group_id="O2" value="1.88" spread="0.477"/>
                    <measurement group_id="O3" value="1.78" spread="0.411"/>
                    <measurement group_id="O4" value="2.90">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="1.43" spread="0.427"/>
                    <measurement group_id="O6" value="0.87" spread="0.232"/>
                    <measurement group_id="O7" value="0.54" spread="0.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)</title>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)</title>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.65" spread="4.673"/>
                    <measurement group_id="O2" value="4.56" spread="1.029"/>
                    <measurement group_id="O3" value="2.89" spread="0.936"/>
                    <measurement group_id="O4" value="4.59">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="3.63" spread="2.125"/>
                    <measurement group_id="O6" value="1.27" spread="0.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)</title>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)</title>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.60" spread="5.149"/>
                    <measurement group_id="O2" value="2.93" spread="0.582"/>
                    <measurement group_id="O3" value="2.73" spread="1.528"/>
                    <measurement group_id="O4" value="4.43">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="2.77" spread="1.197"/>
                    <measurement group_id="O6" value="1.48" spread="0.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)</title>
        <description>Fe=[Ae(0-24)/dose]×100 (molecular weight adjusted for metabolites.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)</title>
          <description>Fe=[Ae(0-24)/dose]×100 (molecular weight adjusted for metabolites.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.65" spread="7.302"/>
                    <measurement group_id="O2" value="9.50" spread="2.144"/>
                    <measurement group_id="O3" value="9.04" spread="2.925"/>
                    <measurement group_id="O4" value="9.57">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="11.36" spread="6.639"/>
                    <measurement group_id="O6" value="7.94" spread="3.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)</title>
        <description>Fe=[Ae(0-24)/dose]×100 (molecular weight adjusted for metabolites.</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)</title>
          <description>Fe=[Ae(0-24)/dose]×100 (molecular weight adjusted for metabolites.</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.01" spread="8.581"/>
                    <measurement group_id="O2" value="6.55" spread="1.293"/>
                    <measurement group_id="O3" value="9.11" spread="5.094"/>
                    <measurement group_id="O4" value="9.85">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="9.22" spread="3.991"/>
                    <measurement group_id="O6" value="9.89" spread="1.896"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)</title>
        <description>Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)</title>
          <description>Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.130"/>
                    <measurement group_id="O2" value="0.22" spread="0.051"/>
                    <measurement group_id="O3" value="0.17" spread="0.077"/>
                    <measurement group_id="O4" value="0.29">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="0.15" spread="0.069"/>
                    <measurement group_id="O6" value="0.07" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)</title>
        <description>Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).</description>
        <time_frame>Day 1</time_frame>
        <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Healthy Adults</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 60 mg</title>
            <description>Azilsartan medoxomil 60 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O5">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 40 mg</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, one day only</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20 mg</title>
            <description>Azilsartan medoxomil 20 mg, tablets, orally, one day only</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)</title>
          <description>Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).</description>
          <population>Pharmacokinetic Set; Results are presented by individual dose for Cohorts 1 and 2.</population>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.309"/>
                    <measurement group_id="O2" value="0.37" spread="0.084"/>
                    <measurement group_id="O3" value="0.34" spread="0.146"/>
                    <measurement group_id="O4" value="0.60">Standard deviation can not be calculated for 1 participant.</measurement>
                    <measurement group_id="O5" value="0.36" spread="0.099"/>
                    <measurement group_id="O6" value="0.16" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>A treatment-emergent adverse event (TEAE) had an onset occurring after the first dose of study medication and within 14 days after the last dose of study medication or, if an SAE, within 30 days after last dose of study medication.</time_frame>
      <desc>At each visit the investigator assessed whether any subjective adverse events have occurred and had to document any occurrence of adverse events and clinically significant abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Healthy Adults</title>
          <description>Azilsartan medoxomil 80 mg, tablets, orally, one day only</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1: Adolescents (≥12 to &lt;17 Years Old) 40-60 mg</title>
          <description>Azilsartan medoxomil 40-60 mg, tablets, orally, one day only. Dose regimen was based on body weight. Participants 40 to &lt; 80 kg received a 40 mg dose and participants 80 to 100 kg received a 60 mg dose.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2: Children (≥6 to &lt;12 Years Old) 20-60 mg</title>
          <description>Azilsartan medoxomil 20-60 mg, tablets, orally, one day only. Dose regimen was based on body weight. Participants 20 to &lt; 40 kg received a 20 mg dose, participants 40 to &lt; 80 kg received a 40 mg dose and participants 80 to 100 kg received a 60 mg dose.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3: Children (≥1 to &lt;6 Years Old)</title>
          <description>Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication related to study results will be made without Sponsor’s prior written approval. Any proposed publication or presentation will be submitted to Sponsor for review 60 days in advance of publication. Institution will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for an additional 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was discontinued without complete enrollment of Cohort 3. Therefore, PK modeling will be used to determine the appropriate doses in children 1 to &lt;6 years of age, in lieu of completing Cohort 3.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

